Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY: CYBN )

7.480 +0.180 (+2.47%)
Streaming Delayed Price Updated: 11:30 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
33 34 35 36 37 38 39 40 Next >
The Psychedelic & Marijuana Drug Stocks Index Dropped -30% In January
This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses. 
Via Talk Markets
Psychedelic Stock Gainers And Losers From January 28, 2022
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 17.86% at $0.57 
Via Benzinga
Cybin's Vision Strengthens Position In Emerging Wellness Trend
Psychedelics pose potential as effective treatments for mental-health issues such as depression, anxiety, and substance abuse Well+Good says psychedelics “poised to change the course of mental health... 
Via Benzinga
Cybin’s (NEO: CYBN) (NYSE American: CYBN) Vision Strengthens Position in Emerging Wellness Trend
Via Investor Brand Network
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Cybin Schedules Release of Q3 Results, Conference Call
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 6.29% at $0.49 
Via Benzinga
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Vision Strengthens Company’s Position in Emerging Wellness Trend
Via Investor Brand Network
Cybin (NYSE American: CYBN) (NEO: CYBN) Schedules Release of Q3 Results, Conference Call
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Scheduled Release of Q3 Financial Results, Conference Call
Via Investor Brand Network
Cybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022
From Cybin Inc.
Via Business Wire
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC: 
Via Benzinga
Mind Medicine, Mindset Pharma Among Top Psychedelic Movers Of Today
GAINERS: Mind Medicine (NASDAQ: 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2022
GAINERS: Field Trip Health (NASDAQ: 
Via Benzinga
Weekend Update: Only 2 Psychedelic Drug Stocks Are Up YTD
This article updates the performances of the 16 largest capitalized clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses out of a... 
Via Talk Markets
Psychedelic Stock Gainers And Losers From January 21, 2022
GAINERS: GH Research (NASDAQ: 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 20, 2022
GAINERS: Small Pharma (OTC: 
Via Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC: 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Strengthening ‘Emerging Best-in-Class Position’ in Evolving Industry
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Psychedelic Stock Gainers And Losers From January 18, 2022
GAINERS: Cybin (AMEX: 
Via Benzinga
Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS
New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: 
Via Benzinga
Cybin Notes 'Milestone' Step with USPTO Notice of Allowance for CYB004
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advi... 
Via Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) Notes ‘Milestone’ Step with USPTO Notice of Allowance for CYB004
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes ‘Milestone’ Step with USPTO Notice of Allowance CYB004
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana
On Tuesday, three public companies in the psychedelics/biotech space announced significant milestones in their drug development pipelines. 
Via Benzinga
Cybin CEO Participation in Upcoming Events Recognizes Company Expertise
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advi... 
Via Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Participation in Upcoming Events Recognizes Company Expertise
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures IRB Approval for Feasibility Study Using Kernel’s Quantitative Neuroimaging Technology
Via Investor Brand Network
Why Cybin Shares Are Rising
Cybin Inc (NASDAQ: CYBN) shares are trading higher after the company announced an Institutional Review Board granted approval for a Cybin-sponsored feasibility study using Kernel... 
Via Benzinga
Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain
From Cybin Inc.
Via Business Wire
< Previous 1 2
...
33 34 35 36 37 38 39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.